Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 230

1.

Heated (37 degrees C) oxaliplatin infusion in combination with capecitabine for metastatic colorectal carcinoma: can it reduce neuropathy?

Cathomas R, Köberle D, Ruhstaller T, Mayer G, Räss A, Mey U, von Moos R.

Support Care Cancer. 2010 Oct;18(10):1263-70. doi: 10.1007/s00520-009-0740-1. Epub 2009 Sep 12.

PMID:
19756772
2.
3.

Treatment of advanced colorectal carcinoma with oxaliplatin and capecitabine: a phase II trial.

Shields AF, Zalupski MM, Marshall JL, Meropol NJ.

Cancer. 2004 Feb 1;100(3):531-7.

4.

Capecitabine plus oxaliplatin for the first-line treatment of elderly patients with metastatic colorectal carcinoma: final results of the Southern Italy Cooperative Oncology Group Trial 0108.

Comella P, Natale D, Farris A, Gambardella A, Maiorino L, Massidda B, Casaretti R, Tafuto S, Lorusso V, Leo S, Cannone M.

Cancer. 2005 Jul 15;104(2):282-9.

5.

Continuous infusion of oxaliplatin plus chronomodulated capecitabine in 5-fluorouracil- and irinotecan-resistant advanced colorectal cancer patients.

Santini D, Vincenzi B, La Cesa A, Caricato M, Schiavon G, Spalletta B, Di Seri M, Coppola R, Rocci L, Tonini G.

Oncology. 2005;69(1):27-34. Epub 2005 Jul 28.

PMID:
16088232
6.

A phase Ib dose-escalation study of erlotinib, capecitabine and oxaliplatin in metastatic colorectal cancer patients.

Van Cutsem E, Verslype C, Beale P, Clarke S, Bugat R, Rakhit A, Fettner SH, Brennscheidt U, Feyereislova A, Delord JP.

Ann Oncol. 2008 Feb;19(2):332-9. Epub 2007 Nov 6.

7.

Capecitabine (Xeloda) in combination with oxaliplatin: a phase I, dose-escalation study in patients with advanced or metastatic solid tumors.

Díaz-Rubio E, Evans TR, Tabemero J, Cassidy J, Sastre J, Eatock M, Bisset D, Regueiro P, Baselga J.

Ann Oncol. 2002 Apr;13(4):558-65.

8.

The combination of capecitabine and irinotecan in treating 5-Fluorouracil- and Oxaliplatin-pretreated metastatic colorectal cancer.

Shin SJ, Ahn JB, Choi HJ, Cho BC, Jeung HC, Rha SY, Chung HC, Roh JK.

Cancer Chemother Pharmacol. 2008 Jan;61(1):75-81. Epub 2007 Mar 21.

PMID:
17375304
9.

Short-time infusion of oxaliplatin in combination with capecitabine (XELOX30) as second-line therapy in patients with advanced colorectal cancer after failure to irinotecan and 5-fluorouracil.

Pfeiffer P, Sørbye H, Ehrsson H, Fokstuen T, Mortensen JP, Baltesgard L, Tveit KM, Øgreid D, Starkhammar H, Wallin I, Qvortrup C, Glimelius B.

Ann Oncol. 2006 Feb;17(2):252-8. Epub 2005 Nov 15.

10.

A multicenter phase II study of the combination of oxaliplatin, irinotecan and capecitabine in the first-line treatment of metastatic colorectal cancer.

Vasile E, Masi G, Fornaro L, Cupini S, Loupakis F, Bursi S, Petrini I, Di Donato S, Brunetti IM, Ricci S, Antonuzzo A, Chiara S, Amoroso D, Andreuccetti M, Falcone A.

Br J Cancer. 2009 Jun 2;100(11):1720-4. doi: 10.1038/sj.bjc.6605075. Epub 2009 May 12.

11.

Phase II study of short-course capecitabine plus oxaliplatin (XELOX) followed by maintenance capecitabine in advanced colorectal cancer: XelQuali study.

Waddell T, Gollins S, Soe W, Valle J, Allen J, Bentley D, Morris J, Lloyd A, Swindell R, Taylor MB, Saunders MP.

Cancer Chemother Pharmacol. 2011 May;67(5):1111-7. doi: 10.1007/s00280-010-1322-0. Epub 2010 Jul 30.

PMID:
20676676
12.

Phase I study of 3-weekly docetaxel, capecitabine and oxaliplatin combination chemotherapy in patients with previously untreated advanced gastric cancer.

Sym SJ, Ryu MH, Kang HJ, Lee SS, Chang HM, Lee JL, Kim TW, Yook JH, Oh ST, Kim BS, Kang YK.

Cancer Chemother Pharmacol. 2010 Jul;66(2):373-80. doi: 10.1007/s00280-009-1171-x. Epub 2009 Nov 21.

PMID:
19936751
13.

Phase II study of capecitabine and oxaliplatin in first- and second-line treatment of advanced or metastatic colorectal cancer.

Borner MM, Dietrich D, Stupp R, Morant R, Honegger H, Wernli M, Herrmann R, Pestalozzi BC, Saletti P, Hanselmann S, Müller S, Brauchli P, Castiglione-Gertsch M, Goldhirsch A, Roth AD.

J Clin Oncol. 2002 Apr 1;20(7):1759-66.

PMID:
11919232
14.

Survey of oxaliplatin-associated neurotoxicity using an interview-based questionnaire in patients with metastatic colorectal cancer.

Leonard GD, Wright MA, Quinn MG, Fioravanti S, Harold N, Schuler B, Thomas RR, Grem JL.

BMC Cancer. 2005 Sep 16;5:116.

15.

Use of calcium and magnesium infusions in prevention of oxaliplatin induced sensory neuropathy.

Chay WY, Tan SH, Lo YL, Ong SY, Ng HC, Gao F, Koo WH, Choo SP.

Asia Pac J Clin Oncol. 2010 Dec;6(4):270-7. doi: 10.1111/j.1743-7563.2010.01344.x.

PMID:
21114776
16.

Multicenter phase II study of fixed sequences of capecitabine combined with oxaliplatin or irinotecan in patients with previously untreated metastatic colorectal cancer.

Cassinello J, Alvarez JV, López MJ, Pujol E, Colmenarejo A, Segovia F, Marcos F, Filipovich E, Arcediano A, Castro IG.

Clin Colorectal Cancer. 2006 Mar;5(6):429-35.

PMID:
16635282
17.

A tailored regimen including capecitabine and oxaliplatin for treating elderly patients with metastatic colorectal carcinoma Southern Italy Cooperative Oncology Group trial 0108.

Comella P, Gambardella A, Farris A, Maiorino L, Natale D, Massidda B, Casaretti R, Tafuto S, Lorusso V, Leo S; Southern Italy Cooperative Oncology Group.

Crit Rev Oncol Hematol. 2005 Feb;53(2):133-9.

PMID:
15661564
18.

Phase II study of capecitabine, oxaliplatin, and erlotinib in previously treated patients with metastastic colorectal cancer.

Meyerhardt JA, Zhu AX, Enzinger PC, Ryan DP, Clark JW, Kulke MH, Earle CC, Vincitore M, Michelini A, Sheehan S, Fuchs CS.

J Clin Oncol. 2006 Apr 20;24(12):1892-7.

19.

XELOX (capecitabine plus oxaliplatin): active first-line therapy for patients with metastatic colorectal cancer.

Cassidy J, Tabernero J, Twelves C, Brunet R, Butts C, Conroy T, Debraud F, Figer A, Grossmann J, Sawada N, Schöffski P, Sobrero A, Van Cutsem E, Díaz-Rubio E.

J Clin Oncol. 2004 Jun 1;22(11):2084-91.

Items per page

Supplemental Content

Write to the Help Desk